Immunovant (IMVT) Interest Coverage Ratio (2019 - 2026)
Immunovant's (IMVT) quarterly Interest Coverage Ratio came in at 0.52 in Q1 2026, little changed YoY from 0.52 in Q1 2025, and up 646.21% on a QoQ basis from 0.07 in Q4 2025.
Immunovant (IMVT) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Immunovant (IMVT) has 8 years of Interest Coverage Ratio data on file, last reported at 0.52 in Q1 2026.
- Quarterly Interest Coverage Ratio changed 0.16% year-over-year to 0.52 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.15 (down 92.66% YoY) and the FY2026 annual result came in at 0.62, up 30.15% from the prior year.
- Interest Coverage Ratio rose to 0.52 in Q1 2026, from 0.07 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.88 in Q4 2023 to a low of 3077.54 in Q2 2022.
- A 5-year average of 195.85 and a median of 0.38 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio plunged 111913.04% — and 2023, when it soared 104.36%.
- Tracing IMVT's Interest Coverage Ratio over 5 years: stood at 0.45 in 2022, then surged by 94.9% to 0.88 in 2023, then tumbled by 56.85% to 0.38 in 2024, then sank by 81.75% to 0.07 in 2025, then jumped by 646.21% to 0.52 in 2026.
- The last three Interest Coverage Ratio figures came in at 0.52 (Q1 2026), 0.07 (Q4 2025), and 1.62 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 0.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.17 |
| Mar 31, 2026 | 0.52 |
| Dec 31, 2025 | 0.07 |
| Sep 30, 2025 | -1.62 |
| Jun 30, 2025 | -0.62 |
| Mar 31, 2025 | 0.52 |
| Dec 31, 2024 | 0.38 |
| Sep 30, 2024 | 0.54 |
| Jun 30, 2024 | 0.60 |
| Mar 31, 2024 | -21.33 |
| Dec 31, 2023 | 0.88 |
| Sep 30, 2023 | 0.85 |
| Jun 30, 2023 | 0.45 |
| Mar 31, 2023 | 0.34 |
| Dec 31, 2022 | 0.45 |
| Sep 30, 2022 | -19.54 |
| Jun 30, 2022 | -3,077.54 |
| Mar 31, 2022 | -214.45 |
| Dec 31, 2021 | -24.27 |
| Sep 30, 2021 | -15.29 |